News

October 22, 2025

HistoSonics Expands Insurance Coverage for Non-Invasive Liver Tumor Treatment to 45.4 Million Elevance Health Members

HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced that Elevance Health (formerly Anthem, […]
October 16, 2025

HistoSonics Announces Oversubscribed $250 Million Growth Financing

HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the closing of an oversubscribed […]
August 8, 2025

Med-tech startup in Plymouth receives $2.25B investment

A nondescript industrial park in Plymouth is home to a med-tech startup that has been making some serious noise for […]
August 7, 2025

HistoSonics Announces $2.25B Acquisition by Consortium of Top-Tier Investors

HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced a management-led majority stake acquisition […]
July 14, 2025

HistoSonics Expands Insurance Coverage for Non-Invasive Liver Tumor Treatment to 7 Million Blue Cross Blue Shield Highmark Members

HistoSonics, the manufacturer of the Edison® Histotripsy System, today announced that Highmark Blue Cross Blue Shield has issued four new […]
June 6, 2025

HistoSonics Completes Enrollment in #HOPE4KIDNEY Trial Evaluating Non-Invasive Histotripsy to Treat Kidney Tumors

HistoSonics, Inc., the manufacturer of the Edison® Histotripsy System and novel histotripsy therapy platforms, today announced the completion of patient […]
1 2 3 8

Last updated on October 22, 2025

Caution: Federal law (USA) restricts this device to sale by or on the order of a physician.

The is intended for the non-invasive mechanical destruction of liver tumors, including the partial or complete destruction of unresectable liver tumors via histotripsy. The FDA has not evaluated the for the treatment of any disease including, but not limited to, cancer or evaluated any specific cancer outcomes (such as local tumor progression, 5-year survival or overall survival). The System should only be used by persons who have completed training performed by HistoSonics Inc., and its use guided by the clinical judgment of an appropriately trained physician. Refer to the device Instructions for Use for a complete list of warnings, precautions and a summary of clinical trial results, including reported adverse events.

Footer last updated on June 30, 2025
X New Twitter Logo
© 2019-2025 HistoSonics®. All rights reserved.
HistoSonics
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.